• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.

作者信息

Cremolini Chiara, Antoniotti Carlotta, Moretto Roberto, Masi Gianluca, Falcone Alfredo

机构信息

Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana; and at the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma, 67, 56126 Pisa, Italy.

出版信息

Nat Rev Clin Oncol. 2017 Feb;14(2):113. doi: 10.1038/nrclinonc.2016.219. Epub 2017 Jan 17.

DOI:10.1038/nrclinonc.2016.219
PMID:28094264
Abstract
摘要

相似文献

1
First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.转移性结直肠癌的一线治疗——原发肿瘤部位对治疗方案的影响
Nat Rev Clin Oncol. 2017 Feb;14(2):113. doi: 10.1038/nrclinonc.2016.219. Epub 2017 Jan 17.
2
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.转移性结直肠癌（mCRC）中抗血管生成治疗的生物标志物：原始数据及文献综述
Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30.
3
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.治疗期间VEGF表达降低可能是转移性结直肠癌患者对一线FOLFIRI联合贝伐单抗治疗反应性的一个预测指标。
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.
4
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.在转移性结直肠癌患者一线治疗中添加贝伐单抗的“现实生活”影响：一项大型以色列回顾性队列研究。
Acta Oncol. 2015 Feb;54(2):164-70. doi: 10.3109/0284186X.2014.958532. Epub 2014 Oct 28.
5
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.伴有靶向药物的转移性结直肠癌二线治疗的二线成本的主张验证算法。
J Med Econ. 2013 Aug;16(8):1071-81. doi: 10.3111/13696998.2013.813513. Epub 2013 Jul 5.
6
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.一项针对RAS野生型转移性结直肠癌患者的表皮生长因子受体抑制剂与贝伐单抗一线头对头试验疗效数据的研究水平荟萃分析。
Eur J Cancer. 2016 Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1.
7
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.原发性肿瘤位置在转移性结直肠癌患者中的相关性：一线临床试验的荟萃分析。
Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.
8
Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.原发性肿瘤定位对贝伐单抗治疗转移性结直肠癌疗效的影响
Anticancer Res. 2018 Sep;38(9):5539-5546. doi: 10.21873/anticanres.12889.
9
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.当前关于晚期或转移性结直肠癌一线治疗中最佳治疗选择的观点：来自阿德莱德结直肠肿瘤组会议的报告；瑞典斯德哥尔摩；2008 年 9 月。
Clin Colorectal Cancer. 2010 Jan;9(1):8-14. doi: 10.3816/CCC.2010.n.001.
10
Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.获得生物制剂与生存率提高的关联：南澳大利亚州（SA）转移性结直肠癌（mCRC）登记处的结果。
Acta Oncol. 2016;55(4):480-5. doi: 10.3109/0284186X.2015.1117135. Epub 2016 Feb 15.

引用本文的文献

1
Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies.左右侧结直肠癌的多维差异及其对靶向治疗的影响。
NPJ Precis Oncol. 2025 Apr 22;9(1):116. doi: 10.1038/s41698-025-00892-y.
2
Outcomes of upfront primary tumor resection in patients with synchronous wild-type metastatic colorectal cancer.同步野生型转移性结直肠癌患者 upfront 原发性肿瘤切除的结局
Am J Cancer Res. 2024 Dec 15;14(12):5863-5873. doi: 10.62347/DLWI1455. eCollection 2024.
3
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.

本文引用的文献

1
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.原发性肿瘤位置在转移性结直肠癌患者中的相关性：一线临床试验的荟萃分析。
Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.
2
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
3
转移性结直肠癌的共识分子亚型可扩大 CMS1 和 CMS2 肿瘤患者基于生物标志物的治疗获益。
Br J Cancer. 2024 Nov;131(8):1328-1339. doi: 10.1038/s41416-024-02826-0. Epub 2024 Sep 4.
4
Loss of and high COX2 () expression in metastatic colorectal cancer.转移性结直肠癌中 的缺失及高环氧化酶2（COX2）表达
Ecancermedicalscience. 2024 Feb 8;18:1666. doi: 10.3332/ecancer.2024.1666. eCollection 2024.
5
Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry.RAS野生型转移性结直肠癌患者一线西妥昔单抗治疗中转移灶切除术的生存获益：一项全国性登记研究
Am J Cancer Res. 2023 Dec 15;13(12):6333-6345. eCollection 2023.
6
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice.转移性结直肠癌、胃癌和胰腺癌患者的原发性肿瘤切除术：寻找为临床实践提供依据的科学证据。
Cancers (Basel). 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900.
7
TRIM27 is an adverse prognostic biomarker and associated with immune and molecular profiles in right-sided colon cancer.TRIM27是一种不良预后生物标志物，与右半结肠癌的免疫和分子特征相关。
Am J Cancer Res. 2022 Nov 15;12(11):4988-5003. eCollection 2022.
8
FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases.FOLFOXIRI方案联合贝伐单抗治疗不可切除肝转移的转移性结直肠癌患者。
Ann Transl Med. 2022 Sep;10(18):952. doi: 10.21037/atm-22-3656.
9
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective.转移性结直肠癌中的生物标志物：现状与未来展望
Cancers (Basel). 2022 Oct 3;14(19):4828. doi: 10.3390/cancers14194828.
10
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.靶向DNA损伤反应通路作为结直肠癌的一种新型治疗策略
Cancers (Basel). 2022 Mar 9;14(6):1388. doi: 10.3390/cancers14061388.
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.
左半结肠癌与右半结肠癌的预后生存情况：一项系统评价与荟萃分析
JAMA Oncol. 2017 Feb 1;3(2):211-219. doi: 10.1001/jamaoncol.2016.4227.
4
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.RAS野生型转移性结直肠癌患者中原发肿瘤部位的预后和预测相关性：CRYSTAL和FIRE-3试验的回顾性分析
JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797.
5
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.RAS和BRAF野生型转移性结直肠癌患者中原发肿瘤的位置及抗表皮生长因子受体单克隆抗体的获益情况
Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5.
6
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.ESMO 共识指南：转移性结直肠癌患者的管理。
Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.
7
The consensus molecular subtypes of colorectal cancer.结直肠癌的共识分子亚型
Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.
8
First-line chemotherapy for mCRC—a review and evidence-based algorithm.mCRC 的一线化疗——综述与循证算法。
Nat Rev Clin Oncol. 2015 Oct;12(10):607-19. doi: 10.1038/nrclinonc.2015.129. Epub 2015 Jul 28.
9
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.结肠癌的位置（右侧与左侧）作为预后因素和西妥昔单抗获益的预测因子在 NCIC CO.17 研究中的体现。
Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.
10
Primary tumor location as a prognostic factor in metastatic colorectal cancer.原发性肿瘤位置作为转移性结直肠癌的一个预后因素
J Natl Cancer Inst. 2015 Feb 24;107(3). doi: 10.1093/jnci/dju427. Print 2015 Mar.